- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00684736
Tryptophan, Serotonin and Kynurenine in Septic Shock (TSK)
August 7, 2008 updated by: Versailles Hospital
Septic shock is a major cause of mortality and morbidity worldwide.
Serotonin (5-HT) is released by activated platelets into the circulation, and is mediator of endothelial dysfunction.
5-HT metabolism is known in immune system via specific 5-HT receptor, also in effects on the peripheral nervous system.
Kinetic of 5-HT, tryptophan, kynurenine, MAO activity and IDO activity in human septic shock was never investigated.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Le Chesnay, France, 78150
- CH Versailles - André Mignot Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients who were 18 years of age or older and had been hospitalized in our ICU were prospectively enrolled in the study if they met all eligibility criteria.
Inclusion criteria were clinical evidence of infection, evidence of a systemic response to infection, and the onset of shock within the previous 3 hours.
Description
Inclusion Criteria:
- Age above or equal to 18 years
- Strong presumption clinical sepsis
- Need for mechanical ventilation
- Body temperature above 38°C or below 36°C
- Heart rate above 90 bpm
- Systolic blood pressure of <90mm Hg despite adequate fluid replacement or a need for vasopressors less than 3 hours
Presence of at least one of the following criteria:
- Ratio of arterial oxygen tension over inspired fraction of oxygen of less than 300 mm Hg
- Urinary output below 0.5 mL per kg of bodyweight per h or below 30 mL/h (for at least 1 h)
- Arterial lactate concentration above 2 mmol/L
- Consent signed
Exclusion Criteria:
- Age below 18 years
- Pregnancy
- Underlying disease with a poor prognosis, a life expectancy of less than 24 hours
- Depression or melancholy
- Neuropsychiatric diseases: Seizure, manic psychosis, Migraine, or Drug addiction
- Neuroendocrine tumors
- Obstructive cardiomyopathy or acute myocardial ischaemia
- Pulmonary embolism
- Advanced stage cancer, malignant haemopathy, or AIDS with a decision to withhold or withdraw aggressive therapies
- Inclusion in another clinical trial
- Patient who receive before inclusion one of the following treatment known to modify serotonin level: almotriptan, amitriptyline, amoxapine, citalopram, clomipramine, clozapine, desipramine, dihydroergotamine, dolasetron, dosulepin, doxepin, eletriptan, ergotamine, flunarizine, fluoxetine, fluvoxamine, granisetron, imipramine, indoramin, interferon Alfa, interferon alfacon-1, interferon beta, iproniazid, maprotiline, methysergide, mianserin, Milnacipran, mirtazapine, moclobemide, naratriptan, olanzapine, ondansetron, oxetorone, paroxetine, pizotifen, risperidone, sertraline, sumatriptan, tianeptine, trimipramine, tropisetron, venlafaxine,viloxazine, zolmitriptan.
- No consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Kinetics of 5-HT, 5-HIAA, kynurenine, tryptophan, HVA, VMA, DOPAC, Oestradiol, Cotinine and vasopressors
Time Frame: Day-1, Day-2, Day-3, Day-7 and Day-14
|
Day-1, Day-2, Day-3, Day-7 and Day-14
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality
Time Frame: 28-day
|
28-day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Jean-Pierre Bédos, MD, PhD, Versailles Hospital
- Study Director: Odile Spreux-Varoquaux, PhD, Versailles Hospital
- Principal Investigator: Matthieu Henry-Lagarrigue, MD, Versailles Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Primary Completion (ACTUAL)
April 1, 2007
Study Completion (ACTUAL)
April 1, 2008
Study Registration Dates
First Submitted
May 22, 2008
First Submitted That Met QC Criteria
May 27, 2008
First Posted (ESTIMATE)
May 28, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
August 8, 2008
Last Update Submitted That Met QC Criteria
August 7, 2008
Last Verified
May 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TSK Sepsis
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock, Septic
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Rennes University HospitalTerminated